JPWO2021232162A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021232162A5 JPWO2021232162A5 JP2022571751A JP2022571751A JPWO2021232162A5 JP WO2021232162 A5 JPWO2021232162 A5 JP WO2021232162A5 JP 2022571751 A JP2022571751 A JP 2022571751A JP 2022571751 A JP2022571751 A JP 2022571751A JP WO2021232162 A5 JPWO2021232162 A5 JP WO2021232162A5
- Authority
- JP
- Japan
- Prior art keywords
- mutation
- variant
- polypeptide
- polypeptide comprises
- heterodimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 claims description 408
- 229920001184 polypeptide Polymers 0.000 claims description 325
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 325
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 325
- 229910052739 hydrogen Inorganic materials 0.000 claims description 52
- 150000001413 amino acids Chemical class 0.000 claims description 47
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 31
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 31
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 229940027941 immunoglobulin g Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229910052698 phosphorus Inorganic materials 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000004251 Ammonium lactate Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000126 in silico method Methods 0.000 claims description 2
- 239000000626 magnesium lactate Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027787P | 2020-05-20 | 2020-05-20 | |
| US63/027,787 | 2020-05-20 | ||
| PCT/CA2021/050690 WO2021232162A1 (en) | 2020-05-20 | 2021-05-20 | Heterodimeric fc variants selective for fc gamma riib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526113A JP2023526113A (ja) | 2023-06-20 |
| JPWO2021232162A5 true JPWO2021232162A5 (zh) | 2024-05-28 |
Family
ID=78708883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571751A Pending JP2023526113A (ja) | 2020-05-20 | 2021-05-20 | ＦｃガンマＲＩＩＢに対して選択的なヘテロ二量体Ｆｃバリアント |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4153621A1 (zh) |
| JP (1) | JP2023526113A (zh) |
| KR (1) | KR20230030577A (zh) |
| CN (1) | CN116113434A (zh) |
| AU (1) | AU2021275453A1 (zh) |
| BR (1) | BR112022023566A2 (zh) |
| CA (1) | CA3144734A1 (zh) |
| MX (1) | MX2022014452A (zh) |
| WO (1) | WO2021232162A1 (zh) |
-
2021
- 2021-05-20 KR KR1020227044652A patent/KR20230030577A/ko active Search and Examination
- 2021-05-20 EP EP21808059.6A patent/EP4153621A1/en active Pending
- 2021-05-20 WO PCT/CA2021/050690 patent/WO2021232162A1/en unknown
- 2021-05-20 BR BR112022023566A patent/BR112022023566A2/pt unknown
- 2021-05-20 JP JP2022571751A patent/JP2023526113A/ja active Pending
- 2021-05-20 CA CA3144734A patent/CA3144734A1/en active Pending
- 2021-05-20 AU AU2021275453A patent/AU2021275453A1/en active Pending
- 2021-05-20 CN CN202180059596.0A patent/CN116113434A/zh active Pending
- 2021-05-20 MX MX2022014452A patent/MX2022014452A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2638568T3 (es) | Variantes de Fc optimizadas y métodos para su generación | |
| EP3148580B1 (en) | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof | |
| AU2018214151B2 (en) | Pd-1-binding molecules and methods of use thereof | |
| US9751942B2 (en) | Anti-LAMP5 antibody and utilization thereof | |
| CN103025761B (zh) | 人源化抗白介素3受体α链抗体 | |
| ES2654937T3 (es) | Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos | |
| AU2012361510B9 (en) | Humanized anti-Epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient | |
| US20230007977A1 (en) | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof | |
| US20110206701A1 (en) | Use of anti-cs1 antibodies for treatment of rare lymphomas | |
| JP2013528357A5 (zh) | ||
| JP2016515120A (ja) | 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防 | |
| EA034757B1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| WO2014138805A1 (en) | Anti il-3r alpha agents and uses thereof | |
| EP1701979A2 (en) | Optimized antibodies that target the epidermal growth factor receptor | |
| JP2013535970A5 (zh) | ||
| JPWO2021232162A5 (zh) | ||
| WO2014143739A2 (en) | Anti-alpha v beta 6 antibodies and uses thereof | |
| US20230406961A1 (en) | Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies | |
| WO2024068777A1 (en) | Modified ace2 proteins with improved activity against sars-cov-2 |